About Guangdong Hybribio Biotech Company

The company is a domestic nucleic acid molecular diagnostic product developer and supplier, focusing on R&D, production and sales of nucleic acid diagnosis-related products such as molecular diagnostic reagents and supporting instruments for molecular diagnosis and providing related services. In 2016, the “Human Papillomavirus Genotyping Kit and Its Gene Chip Preparation Method (ZL200710030723.6)” won the 18th China Invention Patent Gold Award, representing the advanced level of independent innovation in HPV testing in China. On April 12, 2017, the company made its initial public offering of shares and listed on the GEM. As a leading integrated provider of molecular diagnostic products and services in China, the company has outstanding advantages in the fields of early tumor screening, infectious and hereditary diseases. It independently develops, produces and sells a series of products such as tumor testing, maternal and child health, birth defects, and infectious disease testing, and provides related services. The main products include cervical cancer HPV, deafness predisposition genes, nucleic acid testing reagent products for hepatitis B, genital infections, respiratory infections, etc., and drug testing products such as clopidogrel, nitroglycerin, warfarin, folic acid, statins, and early assessment of Alzheimer's disease. The company has received honors such as the Credit Enterprise Honorary Certificate, the “Model Charity Award for Supporting Women's Charity”, the “China Women's Charity Award”, and the Chaozhou Advanced Work Safety Unit. In 2021, it was awarded a social welfare award by the China Cancer Foundation, etc.